Wilson Sonsini Goodrich & Rosati advised Foresight Diagnostics on the transaction. Allogene Therapeutics Inc. (Nasdaq: ALLO) and Foresight Diagnostics, announced a strategic partnership to develop a minimal residual...
Foresight Diagnostics’ Partnership with Allogene Therapeutics
Foresight Diagnostics’ $58.75 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Foresight on the deal. Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced the close of an...